

Form PTO-1449

INFORMATION DISCLOSURE CITATION  
PRIORITY APPLICATION

Docket Number 5322120002000

Application Number 09/28,047

Applicant

Thomas L. CANTOR

Filing Date August 10, 2001

Group Art Unit 1614

Mailing Date October 1, 2002

RECEIVED  
OCT 17 2002  
FBI-NEW YORK

## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
D8 ↓ ✓	1		09 231,422				January 14, 1999
	2		09 344,639				June 26, 1999
	3		09,928,047				August 10, 2001
	4		09/636,530				August 10, 2001
	5		09/636,531				August 10, 2000
	6		10/002,818				November 2, 2001
	7		60/224,396				August 10, 2000
	8		09/928,048				August 10, 2001
	9		09/323,606				June 2, 1999
	10	01/1983	4,369,138	Lindall	260	112.5	
	11	12/1983	4,423,037	Rosenblatt et al.	424	177	
	12	04/1985	4,508,828	Lindall et al.	436	500	
	13	04/1987	4,656,250	Morita et al.	530	324	
	14	02/2000	6,030,790	Adermann et al.	435	7.1	
	15	04/2000	6,051,686	Krstenansky et al.	530	333	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
D8 ↓ ✓	16	07 1985	DE 33 47 548	Germany			
	17	04 1996	DE 44 34 551	Germany			
	18	12 2001	EP 0 783 522	Europe			
	19	05 1991	WO 91 06564	PCT			
	20	04 1993	WO 93 06845	PCT			
	21	02 1994	WO 94 03201	PCT			

EXAMINER:

Dong Jiang

DATE CONSIDERED:

1/6/04

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

Docket Number 832212000200

Application Number 09/028,047

Applicant

Thomas L. CANTOR

Filing Date August 10, 2001

Group Art Unit 1614

Mailing Date October 1, 2002

22.

04 1996

WO 96 10041

PCT

## OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
DJ	23.	Adermann et al., in: Innovations and Perspectives in Solid Phase Synthesis, Epton (ed.), Mayflower World Wide, Birmingham (1994) pp.429-432
	24.	Atkinson et al., Journal of Immunoassay (1982) 3(1):31-51
	25.	Blind et al., Clin. Chem. (1987) 33(8):1376-1381
	26.	Bowie et al., Science (1990) 247:1306-1310
	27.	Brossard et al., Journal of Clinical Endocrinology and Metabolism (1996) 81(11):3923-3929
	28.	Campbell, Monoclonal Antibody and Immunosensor Technology, in Laboratory Techniques in Biochemistry and Molecular Biology, van der Vliet (ed.), Elsevier (1991) pp.1-11, 42-45
	29.	Caporale and Rosenblatt, Parathyroid Hormone Antagonists Effective in vivo, in: Advances in Experimental Medicine and Biology, New York (1986) pp. 315-327
	30.	Clinical Chemistry (1999) 45(6)Suppl:A97 b, Abstract Nos. 339-341
	31.	D'Amour et al., Am. J. Physiol. (1986) 251:E680-E687
	32.	Daniel et al., Virology (1994) 202:540-549
	33.	Divieti, P. et al. (2001). J Bone Miner Res 2001:Suppl 1, S307.
	34.	Faugere, M.C. et al. (2001). Kidney International 60:1460-1468.
	35.	Faugere, M.C. et al. Nephrology, Bone & Mineral Metabolism A3995.
	36.	Fischer et al., The Journal of Clinical Investigation (1974) 54:1382-1394
	37.	Gao et al., Clinica Chimica Acta (1996) 245:39-59
	38.	Goodman, W. et al. (2000). NEJM 342:20, 1478-1483.
	39.	Gordon et al., Parathyroid Hormone Domain for Protein Kinase C Stimulation Located within Amphiphilic Helix, in: Peptides: Chemistry and Biology, Proceedings of the Twelfth American Peptide Symposium, June 16-21, 1991, Cambridge, MA, Smith and Rivier (eds.) Escom Science Publishers (1992) pp.37-39
	40.	Hashimoto et al., Journal of Cardiovascular Pharmacology (1981) 3(4):668-676
	41.	Hehrmann et al., Journal of Immunoassay (1980) 1(2):151-174
	42.	John et al., Journal of Clinical Endocrinology and Metabolism (1999) 84(11):4287-4290
	43.	LePage et al., Clin. Chem. (1998) 44:805-810

EXAMINER:

Dong Jiang

DATE CONSIDERED:

1/6/04

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

Docket Number 532212000200

Application Number 09/028,017

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION


Applicant

Thomas L. CANIOR

Filing Date August 10, 2001

Group Art Unit 1614

Mailing Date October 4, 2002



44	Logue et al., Journal of Immunological Methods (1991) 137:159-166
45	Mägerlein et al., Arzneim.-Forsch. Drug Res. (1998) 48(1):197-204
46	Mägerlein et al., Arzneim.-Forsch. Drug Res. (1998) 48(II):783-787
47	Mallette, Journal of Clinical Endocrinology and Metabolism (1980) 50(1):201-203
48	Nakamura et al., Endocrinol. JPN (1981) 28(4):547-549
49	Ngo et al., The Protein Folding Problem and Tertiary Structure Prediction, Merz et al., (eds.), Birkhäuser Boston (1994) pp.492-495
50	Niall et al., Proc. Natl. Acad. Sci. USA (1974) 71(2):384-388
51	Nussbaum et al., Chemical Abstracts (1982) 96(5):181-192
52	Pang et al., Pharmacol. Exp. Ther. (1981) 216(3):567-571
53	Podbesek et al. (1983). Endocrinology 112(3):1000-1006
54	Qi et al., Am. J. Kidney Dis. (1995) 26:622-631
55	Quarles et al., J. Clin. Endocrinol. Metab. (1992) 75:145-150
56	Stadler, Homologous Radioimmunoassay for Human Parathyroid Hormone (Residues 1-34) with Biotinylated Peptide as Tracer, in Calcium Regulating Hormones, Vitamin D Metabolites, and Cyclic AMP Assays and their Clinical Application, Schmidt-Gayk et al., (eds.), Berlin/Heidelberg, Springer, (1990) pp. 137-150
57	Tampe et al., J. Immunoassay (1992) 13(1):1-13
58	Visser et al., Acta Endocrinology (1979) 90:90-102
59	Wingender et al., Structure-Function Relationship in Parathyroid Hormone in: Advances in Protein Design, International Workshop, Blöcker et al. (eds.), VCH (1988) pp.167-176
60	Zanelli et al., Journal of Immunoassay (1983) 4(2):175-206
61	Zemplar package insert, Abbott Reference (1998). 06-9998-R1-Rev. Roche Laboratories.

RECEIVED  
OCT 15 2002  
TECH. CENTER 1600 2900

EXAMINER:

*Dong Jiang*

DATE CONSIDERED:

*1/6/04*

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.